1
|
Gu Y, Chang TTA, Wang J, Jaiswal JK, Edwards D, Downes NJ, Liyanage HDS, Lynch CRH, Pruijn FB, Hickey AJR, Hay MP, Wilson WR, Hicks KO. Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice. Front Pharmacol 2017; 8:531. [PMID: 28848445 PMCID: PMC5554537 DOI: 10.3389/fphar.2017.00531] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2017] [Accepted: 07/28/2017] [Indexed: 12/23/2022] Open
Abstract
3-(3-Morpholinopropyl)-7,8-dihydro-6H-indeno[5,6-e][1,2,4]triazine 1,4-dioxide (SN30- 000), an analog of the well-studied bioreductive prodrug tirapazamine (TPZ), has improved activity against hypoxic cells in tumor xenografts. However, little is known about its biotransformation in normal tissues. Here, we evaluate implications of biotransformation of SN30000 for its toxicokinetics in NIH-III mice. The metabolite profile demonstrated reduction to the 1-N-oxide (M14), oxidation of the morpholine side-chain (predominantly to the alkanoic acid M18) and chromophore, and subsequent glucuronidation. Plasma pharmacokinetics of SN30000 and its reduced metabolites was unaffected by the presence of HT29 tumor xenografts, indicating extensive reduction in normal tissues. This bioreductive metabolism, as modeled by hepatic S9 preparations, was strongly inhibited by oxygen indicating that it proceeds via the one-electron (radical) intermediate previously implicated in induction of DNA double strand breaks and cytotoxicity by SN30000. Plasma pharmacokinetics of SN30000 and M14 (but not M18) corresponded closely to the timing of reversible acute clinical signs (reduced mobility) and marked hypothermia (rectal temperature drop of ∼8°C at nadir following the maximum tolerated dose). Similar acute toxicity was elicited by dosing with TPZ or M14, although M14 did not induce the kidney and lung histopathology caused by SN30000. M14 also lacked antiproliferative potency in hypoxic cell cultures. In addition M14 showed much slower redox cycling than SN30000 in oxic cultures. Thus a non-bioreductive mechanism, mediated through M14, appears to be responsible for the acute toxicity of SN30000 while late toxicities are consistent with DNA damage resulting from its one-electron reduction. A two-compartment pharmacokinetic model, in which clearance of SN30000 is determined by temperature-dependent bioreductive metabolism to M14, was shown to describe the non-linear PK of SN30000 in mice. This study demonstrates the importance of non-tumor bioreductive metabolism in the toxicology and pharmacokinetics of benzotriazine di-oxides designed to target tumor hypoxia.
Collapse
Affiliation(s)
- Yongchuan Gu
- Experimental Therapeutics Group, Auckland Cancer Society Research Centre, School of Medical Sciences, The University of AucklandAuckland, New Zealand
| | - Tony T-A Chang
- Experimental Therapeutics Group, Auckland Cancer Society Research Centre, School of Medical Sciences, The University of AucklandAuckland, New Zealand
| | - Jingli Wang
- Experimental Therapeutics Group, Auckland Cancer Society Research Centre, School of Medical Sciences, The University of AucklandAuckland, New Zealand
| | - Jagdish K Jaiswal
- Experimental Therapeutics Group, Auckland Cancer Society Research Centre, School of Medical Sciences, The University of AucklandAuckland, New Zealand
| | - David Edwards
- Cancer Research Centre for Drug Development, Cancer Research UK (CRUK)London, United Kingdom
| | | | - H D Sarath Liyanage
- Experimental Therapeutics Group, Auckland Cancer Society Research Centre, School of Medical Sciences, The University of AucklandAuckland, New Zealand
| | - Courtney R H Lynch
- Experimental Therapeutics Group, Auckland Cancer Society Research Centre, School of Medical Sciences, The University of AucklandAuckland, New Zealand
| | - Frederik B Pruijn
- Experimental Therapeutics Group, Auckland Cancer Society Research Centre, School of Medical Sciences, The University of AucklandAuckland, New Zealand
| | - Anthony J R Hickey
- School of Biological Sciences, The University of AucklandAuckland, New Zealand
| | - Michael P Hay
- Experimental Therapeutics Group, Auckland Cancer Society Research Centre, School of Medical Sciences, The University of AucklandAuckland, New Zealand
| | - William R Wilson
- Experimental Therapeutics Group, Auckland Cancer Society Research Centre, School of Medical Sciences, The University of AucklandAuckland, New Zealand
| | - Kevin O Hicks
- Experimental Therapeutics Group, Auckland Cancer Society Research Centre, School of Medical Sciences, The University of AucklandAuckland, New Zealand
| |
Collapse
|
2
|
Martin SK, Diamond P, Gronthos S, Peet DJ, Zannettino ACW. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia 2011; 25:1533-42. [PMID: 21637285 DOI: 10.1038/leu.2011.122] [Citation(s) in RCA: 93] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Hypoxia is an imbalance between oxygen supply and demand, which deprives cells or tissues of sufficient oxygen. It is well-established that hypoxia triggers adaptive responses, which contribute to short- and long-term pathologies such as inflammation, cardiovascular disease and cancer. Induced by both microenvironmental hypoxia and genetic mutations, the elevated expression of the hypoxia-inducible transcription factor-1 (HIF-1) and HIF-2 is a key feature of many human cancers and has been shown to promote cellular processes, which facilitate tumor progression. In this review, we discuss the emerging role of hypoxia and the HIFs in the pathogenesis of multiple myeloma (MM), an incurable hematological malignancy of BM PCs, which reside within the hypoxic BM microenvironment. The need for current and future therapeutic interventions to target HIF-1 and HIF-2 in myeloma will also be discussed.
Collapse
Affiliation(s)
- S K Martin
- Division of Haematology, Centre for Cancer Biology, SA Pathology, CSCR, University of Adelaide, Adelaide, South Australia
| | | | | | | | | |
Collapse
|
3
|
Denny WA. Hypoxia-activated prodrugs in cancer therapy: progress to the clinic. Future Oncol 2010; 6:419-28. [PMID: 20222798 DOI: 10.2217/fon.10.1] [Citation(s) in RCA: 80] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
The hypoxic cells common in solid tumors (because of their inefficient blood supply) limit the effectiveness of radiotherapy and many cytotoxic drugs. Nontoxic prodrugs that generate active species in hypoxic tissue by selective bioreduction have long been explored, and the first examples, representing a variety of different chemistries, have now reached advanced clinical trials. In the process, a great deal has been learnt about the properties that such drugs require to be successful, notably, efficient extravascular diffusion, appropriate reduction chemistry and kinetics, and an effective biological profile of the activated species, including a good bystander effect. The critical importance of prodrug diffusion and techniques to quantify this have assisted the development of models to predict the killing of tumor cells, which promises to help accelerate new drug evaluation. A cell cycle-independent mechanism of killing by the released cytotoxin is also a potential advantage, although it is likely that much of the killing will be when out-of-cycle hypoxic cells reoxygenate and resume division.
Collapse
Affiliation(s)
- William A Denny
- Auckland Cancer Society Research Centre, The University of Auckland, New Zealand.
| |
Collapse
|